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SummaryThe clinical behavior of
localized prostate cancer is
highly variable, with some
cancers remaining indolent
for many years and others
progressing to metastatic
disease in a short time. In
this work, the value of
computed tomography
based radiomics for risk
stratification in prostate can-
cer was investigated. Our
results show that radiomics
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tomographic scans can pro-
vide insight into prostate
cancer aggressiveness in a
noninvasive manner.modest performance was observed for validation on holdout data sets with the highest
AUC of 0.75 for classifiers of low versus high RG and an AUC of 0.70 for GS 7 versus
GS > 7.
Conclusions: Our results show that radiomics features from routinely acquired plan-
ning CT scans could provide insights into prostate cancer aggressiveness in a nonin-
vasive manner. Assessing models on training data sets, the classifiers were especially
accurate in discerning high-risk from low-risk patients and in classifying GS 7 versus
GS > 7 and GS 7(3 þ 4) versus G7(4 þ 3); however, classifiers were less adept at
distinguishing high RG versus intermediate RG. External validation and prospective
studies are warranted to verify the presented findings. These findings could
potentially guide targeted radiation therapy strategies in radical intent radiation
therapy for prostate cancer.  2019 Elsevier Inc. All rights reserved.Introduction
Prostate cancer is one of the most frequently diagnosed
cancers globally; it is the most common cancer in males in
the United Kingdom, with approximately 130 new cases
per day.1 Other than skin cancer, prostate cancer is also the
most common cancer in males in the United States, with
approximately 64,690 new cases per year.2 Traditionally,
prostate cancer is stratified into risk categories using
prostate-specific antigen (PSA) level, biopsy-based Gleason
scores (GSs), and TNM staging.3 Although extremely
useful in assessing prostate cancers, GSs are typically
determined from a limited number of transrectal ultrasound
(TRUS)eguided biopsies that are randomly sampled. This
poses a challenge because prostate cancer is associated with
significant intratumor heterogeneity.4 The behavior of
prostate cancer is also highly variable, with some tumors
progressing rapidly and others remaining indolent for many
years. These factors make early diagnosis, accurate prog-
nosis, and tumor risk stratification critical to increase the
therapeutic ratio and to avoid unnecessary intervention.
Medical scans are conventionally used for diagnosis and
treatment planning; however, in recent years, this role has
expanded to include the extraction and quantification of
imaging features (ie, radiomics analysis) to serve as im-
aging biomarkers for staging and to enhance the perfor-
mance of prognostic and predictive models.5-10 The
prognostic and predictive value of magnetic resonance
imaging (MRI)ebased radiomics features for prostate
cancer has been demonstrated in a number of publica-
tions.8-11 In recent years, there has been an increased focus
on the development of multiparametric MRI (mpMRI) as a
tool for effective image characterization, treatment plan-
ning, and response assessment.12,13 Despite its effective-
ness, there is no clear consensus regarding the most
important imaging biomarkers for prostate or their clinical
applicability, possibly because of the lack of interopera-
bility (ie, variable imaging protocols, scanners, software) or
uncertainties in the manual definition of tumors.14,15 In
contrast to MRI, planning computed tomography (CT)
scans are typically highly standardized, and they are
available for almost all patients treated with external beamradiation therapy for outlining structures of interest, plan-
ning treatments, dose calculation, and as a reference for
image guidance. Several studies have reported high
repeatability and reproducibility of several CT-based
radiomics features extracted from patient and from phan-
toms scans.16 Only a limited number of studies have
investigated reproducibility with MRI scans reporting that
MRI-based radiomics features are less robust.16,17 In radi-
ation therapy, standardized planning CT scans are
frequently assessed for CT number per electron density
calibration, uniformity, and noise because this is critical for
dose calculation; however, because MRI was traditionally
used for visualization, less standardization has typically
been used. Now that the role of medical imaging and
radiomics analysis has been realized, there are more in-
ternational efforts to standardize and control differences in
medical scans to allow their optimal use for prospective
imaging biomarkers studies.18,19
To date, no studies have examined the role of non-
contrast CT-based prostate radiomics in risk stratification or
prognosis. This could be partially due to the poor visual
discrimination of prostate cancer on CT scans; however,
accumulating evidence of the value of imaging in diagnosis
and prognosis of prostate cancer warrants more compre-
hensive investigation.5-11
We hypothesize that the computerized interpretation of
prostate intensity levels and their spatial distribution, as
quantified from CT scans, will reveal additional informa-
tion about prostate cancer, and radiomics analysis could
serve as virtual biopsies.
In this study, we investigate the value of CT-based
radiomics features to classify prostate cancer GS and risk
group (RG). To our knowledge, this is the first investigation
of noncontrast CT-based radiomics features for prostate
cancer.
Methods and Materials
The use of CT scans and disease staging information of the
study population in the present study was approved by the
Belfast Health and Social Care Trust (BHSCT) with
research governance permission number 18042CMcG-SS.
Table 1 Patient grouping based on Gleason Score (GS)
Gleason Score Number of patients
6 (3 þ 3) 100
7 (3 þ 4) 87
7 (4 þ 3) 49
>7 106 (GS 8 Z 55; GS 9 Z 51)
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All patients with localized prostate cancer treated at the
Northern Ireland Cancer Centre (NICC), between January
1, 2005, and December 31, 2009, were considered in this
study. Patients were treated with 70 to 74 Gy external
beam radiation therapy in 2-Gy fractions with 3-
dimensional conformal or intensity modulated radiation
therapy techniques over 7 to 7.5 weeks. Patients had short
(6 months) or long-course (6-36 months) androgen-
deprivation therapy commenced at least 3 months before
radiation with luteinizing hormone-releasing hormone
agonists or antiandrogens monotherapy (bicalutamide 150
mg daily dose). For patients in this cohort, GS was
determined from TRUS biopsies. The median number of
cores was 12 (range, 6-21), and the median volume of the
tissue involved was 20% (range, 1%-90%; statistics
available from 53% of patients). The median volume of
tissue involved in different GS subgroups were: GS 6 Z
7.5%; GS 7(3 þ 4) Z 18.8%; GS 7(4 þ 3) Z 20%; and
GS > 7 Z 20%. Patients were assigned to low-, inter-
mediate-, and high-risk groups based on GS, initial PSA
(iPSA), and TNM stage as per the United Kingdom Na-
tional Institute for Health and Care Excellence
guidelines.20Table 2 Patient grouping based on risk group
Risk group
UK
NICE criteria
Number of
patients
Low risk T1 or T2a,
Gleason score Z 6, and
PSA <10 ng/mL
n Z 33
Intermediate
risk
T2b or T2c, or Gleason
score Z 7, or
PSA Z 10-20 ng/mL
n Z 76
High-risk >T2c,
Gleason score Z 8-10, or
PSA > 20 ng/mL
n Z 233CT image acquisition and image segmentation
Five hundred and six patients were initially identified for
this study, of whom 447 had complete data sets (planning
CT scans (pCT) and structure sets in digital imaging and
communications in medicine (DICOM) format) to qualify
for inclusion in this study. All patients were scanned at the
NICC using our local pelvis protocol on one of two CT
scanners: Emotion 6 (Siemens Health Care, Erlangen,
Germany) and LightSpeed RT (GE Medical Systems,
Chicago). Patients were scanned in helical mode using the
following acquisition parameters: tube current, 370 to 437
mAs for the GE scanner and 130 to 194 mAs for Siemens;
tube voltage, 120 kV(p) for GE and 130 kV(p) for Siemens;
slice thickness, 2.5 mm; standard convolution kernel for GE
and B41s for Siemens; 512  512 pixels; pixel spacing,
0.98 to 1.17 mm. All DICOM images and structure sets
were exported into CERR software and converted to the
MATLAB data file format.21 To reduce contouring vari-
ability, all prostate structures were reviewed and adjusted
when necessary to construct a prostate glandeonly struc-
ture (PO) by a single observer and reviewed by an expe-
rienced consultant clinical oncologist. The PO structure,
which includes the whole prostate, was used for further
analysis. Only CT scans with a 2.5 mm slice thickness and
no artifacts were included in the analysis (eg, patients with
prosthetic hips were excluded). Using these selection
criteria, 342 scans were then identified as suitable for
further analysis. Risk groupings are detailed in Tables 1 and
2 along with the number of patients assigned to each group.Radiomics features extraction
RadiomiX software (Oncoradiomics, Liège, Belgium) was
used to extract 1618 radiomic features from PO structures for
each patient. After an initial investigation on optimal radio-
mics extraction settings (supplementary material Appendix
E1; available online at https://doi.org/10.1016/j.ijrobp.
2019.06.2504), CT scans were resampled to 2.5 mm
isotropic voxels and the range of Hounsfield units (HU)
was discretized to 10 HU bins before features extraction.
Radiomics features extracted were the first-order gray-level
statistics from the intensity level histograms, and features
based on: gray-level co-occurrence matrix (GLCM), gray-
level run-length matrix (GLRLM), gray-level size-zone
matrix (GLSZM), gray-level distance-zone matrix
(GLDZM), neighborhood gray-tone difference matrix
(NGTDM) and neighboring gray-level dependence matrix
(NGLDM). The textural and statistics features were also
calculated after applying 8 subbands of 3-dimensional
wavelet transforms and 16 subbands of Laplacian of
Gaussian (LoG) transform to the scans. A detailed explana-
tion of the extracted features and their mathematical defini-
tions are published elsewhere.6,22 In this analysis, geometric
features (except for prostate volume) were excluded because
the entire prostate gland was contoured and analyzed rather
than tumor specific regions.
Testeretest cohort
Twenty patients with prostate cancer with available pre-
treatment repeated pCT scans were also included in this
study. These patients underwent repeated scans either for
suboptimal bladder or rectal filling or for the temporary
Volume 105  Number 2  2019 Prostate cancer CT-based radiomics 451presence of a rectal gas pocket on the first pCT scans. The
average time between scans and rescans was 11 days
(range, 0-28 days). Radiomics analysis of PO structures
were conducted on the scans and the rescans. The intraclass
correlation coefficient (ICC)23,24 was calculated to provide
an indication of the testeretest repeatability and repro-
ducibility of the features extracted. The intraclass correla-
tion coefficient ranged between 0 and 1, with 0 indicating
no reliability and 1 indicating perfect reliability. A cutoff
value of 0.8 was used to arrive at a set of stable and robust
features set for further analysis.
Feature selection and classification
For each developed model, stratified partitioning was used
to randomly assign 80% of the data for model training and
20% for validation. To reduce the risk of models overfitting,
the following feature reduction methods were used. The
function findCorrelation in the R package Caret was used
to remove (redundant) highly correlated features to reduce
multicolinearity.25-27 This function searches through a
correlation matrix of all the features and returns a vector of
integers corresponding to columns to remove pair-wise
correlations. Generalized linear models, via penalized
maximum likelihood, were fitted using the R package
glmnet and the default parameter tuning with the Caret
interface was used. Two methods of variable selection were
implemented: regularization through (1) the least absolute
shrinkage and selection operator (LASSO) and (2) Elas-
ticNet. Before the analysis, radiomics features were scaled
and centered using Caret’s function PreProc. PreProc
method “centre” centres feature values by subtracting the
mean and the PreProc method “scale” devides by the
standard deviation.25 A grid search was used to choose
optimal model hyperparameters that minimize cross-
validation errors, and hyperparameters one standard error
away from optimal values were then used. The average
predictive performance of each model on the training data
set was estimated using 10-fold cross-validation repeated
100 times. Sample augmentation using the Syntactic Mi-
nority Oversampling TEchnique (SMOTE) for class
balancing in training data was also investigated.28
Statistical analysis and model assessment
Following the guidelines of the transparent reporting of
multivariable prediction model for individual prognosis or
diagnosis statement for type 2a studies (ie, study using a
single data set; data are randomly split into 2 groups: one to
develop the prediction model and one to evaluate its pre-
dictive performance),29 Mann-Whitney U tests (Wilcoxon
rank sum test) were performed to test the null hypothesis
that feature values have equal medians in different patient
risk groups against the alternative that they are not.
In this work, all models were trained with and without
sample augmentation. Model performances were assessedon training and on testing data sets using area under the
receiver operating characteristic curve (AUC), accuracy
(Acc), sensitivity, and specificity and for comparison with
previous work.30 Youden index (YI)31 was also reported
(YI Z specificity þ sensitivity e 1). For all models, the
AUC 95% confidence interval (CI) was computed with
2000 stratified bootstrap replicates.Results
A flow diagram of the study cohort, exclusion criteria, and
premodeling feature filtering is shown in Figure 1. After
applying our exclusion criteria, 342 patients’ CT scans
were eligible for analysis. Forty PO structures from 20
patients were included in the test-retest analysis (Figs. 1
and 2A).
The performance of the trained models for classifying
patients into different GS and risk groups was assessed in
multiple steps (Tables 3 and 4). Sample augmentation
was used to balance training data when required (detailed
analysis of performance of models developed on non-
augmented and augmented data are provided in Tables E1
and E2; available online at https://doi.org/10.1016/j.
ijrobp.2019.06.2504). For example, the first radiomics
classifier was trained to distinguish low from high GS
(GS  6 vs GS  7). Figure 2B shows a circular bar plot
of a subset of robust radiomics features (n Z 114,
unfiltered) in the two patient groups GS  6 and GS  7.
The length of the bar represents the median value of each
feature (scaled and centered), each patient group is rep-
resented with a different color. The stars in the circular
bar plots indicate features that had significantly different
median values in different groups. A comprehensive list
of significant features is provided in Appendix E2
(available online at https://doi.org/10.1016/j.ijrobp.2019.
06.2504).
Assessing the apparent performance of the trained
models on training data, excellent performance was
observed in classifying patients with low GS (GS 6) from
high GS (GS > 6) and low-risk from high-risk patients with
AUC Z 0.90 (95% CI, 0.86-0.95) and AUC Z 0.96 (95%
CI, 0.93-0.98), respectively (Fig. 3; Tables 3 and 4).
Excellent performance was observed for classifiers of GS
7(3 þ 4) versus GS 7(4 þ 3) with an AUC of 0.98 (95% CI,
0.96-1.00) with high specificity and sensitivity. Developed
classifiers had lower performance in distinguishing GS 7
from GS > 7 (AUC Z 0.69; 95% CI, 0.61-0.76). The most
important variables (features) in distinguishing GS and risk
groups were found to be the wavelet transforms of the
NGTDM coarseness (HLL, HLH, HHH) and contrast
(HHH), the low gray-level small dependence emphasis
LGSDE of the NGLDM (HHL, LLL, LHL, HLL), and the
(LLL) GLSZM intensity nonuniformity normalized. All
these features capture different aspects of texture
heterogeneity.
CT scans and GS and risk group  
N = 342
Segmenting PO 
structure N = 342
Test-retest 
dataset
N = 20
Segmenting PO 
structure N = 40
ICC > 0.8
Final set of features to 
use in analysis n = 522 
Yes
include
No  exclude
Filter features
Unreliable features 
no further analysis
Patient population
N = 506
Patients with pCT
N = 447
Patients suitable for final 
analysis N = 342
59 patients excluded 
no pCT scans available
105 patients excluded 
slice thickness ≠2.5mm 
or/and presence of 
artefacts
Radiomics analysis
n = 1618 features 
Radiomics analysis
n = 1618 features 
Fig. 1. Flow diagram of study cohort, radiomics workflow, and radiomics features generated. Patient numbers denoted by N
and features by n.
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data. The resulting AUC are presented in Tables 3 and 4
and Figure 3. The best observed performance was for
classifiers of low-risk versus high-risk cancers, with an
AUC of 0.75 (95% CI, 0.48-1.00) and for GS 7 versus GS
> 7 (AUCZ 0.70; 95% CI, 0.48-0.81). Lower performance
was observed for models of GS 7(3 þ 4) versus GS(4 þ 3)a
150
50
0
0.00 0.25 0.50 0.75 1.00
100
Fe
at
ur
e 
co
un
t
Intraclass Correlation Coefficient (ICC)
n = 1096 n = 522
Stats First order gray-level statistics
Gray-Level Co-occurrence Matrix
Gray-Level Distance-Zone Matrix
Gray-Level Run-Length Matrix
Gray-Level Size-Zone Matrix
Neighbourhood Gray-Level Dependence Matrix
Neighbourhood Gray-Level Difference Matrix
GLCM
GLDZM
GLSZM
NGLDM
NGTDM
GLRLM
Fig. 2. (A) Histogram of the interclass correlation coefficients
The black dotted line indicates the cutoff value of 0.8 for reprodu
stable radiomics features (excluding filtered features) were scaled
in the bar indicate median value of feature in patients with low a
significantly different between the two cohorts with Mann-Whitn
of this figure is available at https://doi.org/10.1016/j.ijrobp.2019and low risk versus intermediate risk (AUC Z 0.65 and
0.49, respectively).
In Figure 3, examples of AUC for different radiomics-
based GS and RG classification are presented for models
developed using ElasticNet on the training data and on
testing data sets. Multiclass models for GS and RG clas-
sification were also explored and results are presented inb
n = 114
Stats GLCM
NGTDM
NGLDM GLDZM
GLSZM GLRLM
for radiomics features (n Z 1618) from the testeretest data.
cible features (n Z 522). (B) A circular stacked bar plot of
and centered for this presentation. Yellow and purple colors
nd high GS cohorts, respectively.*indicates that a feature is
ey U test *P  .05. **P  .01. ***P  .001. (A color version
.06.2504.)
Table 3 Accuracy results for Gleason Score classification using Lasso and elastic Net regularization
Gleason Score
Training Testing
AUC Accuracy YI Gleason Score AUC Accuracy YI
LASSO
GS 6 vs > 6 0.77 0.65 0.50 GS 6 vs > 6 0.59 0.59 0.27
n Z (80 vs 194)* (0.73-0.84) (0.59-0.71) n Z (19 vs 48) (0.42-0.76) (0.46-0.71)
GS 7(3 þ 4) vs 7(4 þ 3) 0.97 0.86 0.66 GS 7(3 þ 4) vs 7(4 þ 3) 0.65 0.5 e0.13
n Z (70 vs 40) (0.95-1) (0.79-0.92) (17 vs 9) (0.41-0.90) (0.30-0.70)
GS 7 vs > 7 0.67 0.62 0.13 GS 7 vs >7 0.70 0.58 0.06
nZ (109 vs 85) (0.59-0.74) (0.55-0.69) (27 vs 21) (0.54-0.86) (0.43-0.72)
ElasticNet
GS 6 vs > 6 0.90 0.86 0.76 GS 6 vs >6 0.60 0.59 0.27
n Z (80 vs 194)* (0.86-0.95) (0.81-0.90) n Z (19 vs 48) (0.43-0.77) (0.46-0.71)
GS 7(3 þ 4) vs 7(4 þ 3) 0.98 0.92 0.80 GS 7(3 þ 4) vs 7(4 þ 3) 0.57 0.65 0.15
n Z (70 vs 40) (0.96-1.00) (0.85-0.96) n Z (17 vs 9) (0.30-0.84) (0.44-0.83)
GS 7 vs > 7 0.69 0.64 0.21 GS 7 vs > 7 0.65 0.58 0.07
n Z (109 vs 85) (0.61-0.76) (0.57-0.71) n Z (27 vs 21) (0.48-0.81) (0.43-0.72)
Abbreviations: AUC Z area under the curve; YI Z Youden index (Sensitivity þ Specificity e 1); vs Z versus; nZ number of patients.
* n is the number of patients in each cohort. The asterisk indicates that training data were augmented before model training.
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ijrobp.2019.06.2504). Both GS and RG multiclass classi-
fiers (built on SMOTEd data) had reasonable apparent
performance on training data; however, only the RG mul-
ticlass classifier showed reasonable accuracy on the test
data set (Acc Z 0.70; 95% CI, 0.47-0.71). Applying
sample augmentation through SMOTE, all the classifiers
outperformed those built on nonaugmented samples with
all models showing high sensitivity and specificity for all
tested cases (Appendix E3; available online at https://doi.
org/10.1016/j.ijrobp.2019.06.2504).
None of the developed classifiers had prostate volume in
the final model. Pairwise t tests were conducted to test
differences in prostate volume different risk groups. NoTable 4 Accuracy results for prostate cancer risk group classificatio
Risk Group
Training
AUC Accuracy YI
LASSO
Low vs high 0.96 0.89 0.87
n Z (26 vs 187)* (0.94-0.99) (0.84-0.93)
Low vs intermediate 1.00 1.00 1.00
n Z (33 vs 76) (1.00-1.00) (0.96-1.00)
Intermediate vs high 1.00 0.99 0.97
n Z (61 of 187)* (1.00-1.00) (0.99-0.98)
ElasticNet
Low vs high 0.96 0.88 0.87
n Z (26 of 187)* (0.93-0.98) (0.65-0.89)
Low vs intermediate 1.00 1.00 1.00
n Z (33 of 76) (1.00-1.00) (1.00-1.00)
Intermediate vs high 1.00 0.99 0.97
n Z (61 of 187)* (1.00-1.00) (0.99-0.98)
Abbreviations: AUC Z area under the curve; YI Z Youden index (Sensitiv
* n is the number of patients in each cohort. The asterisk indicates that traisignificant differences in prostate volume were found be-
tween different GS groups or between different androgen-
deprivation therapy types; however, prostate volume was
significantly larger in the intermediate- versus high-risk
group (P Z .02; Figure E1; available online at https://
doi.org/10.1016/j.ijrobp.2019.06.2504).
Pearson and Spearman correlation coefficients were also
calculated for the 20 most important variables, picked by
each classifier (Figure E2; available online at https://doi.
org/10.1016/j.ijrobp.2019.06.2504). The cross-correlation
of patients’ (initial) PSA, GS, risk group (RG), and pros-
tate volumes (PV) with radiomics features revealed only
weak correlations between individual radiomics features
and clinical factors. It is also observed that severaln using Lasso and elasticNet regularization
Testing
Risk Group AUC Accuracy YI
Low vs high 0.71 0.79 e0.29
n Z (6 vs 46) (0.46-0.96) (0.65-0.89)
Low vs intermediate 0.56 0.71 0.30
n Z (6 vs 15) (0.21-0.90) (0.48-0.89)
Intermediate vs high 0.49 0.54 e0.10
n Z (15 vs 46) (0.33-0.63) (0.41-0.67)
Low vs high 0.75 0.83 0.54
n Z (6 vs 46) (0.48-1.00) (0.72-0.93)
Low vs intermediate 0.56 0.71 0.30
n Z (6 vs 15) (0.21-0.91) (0.48-0.89)
Intermediate vs high 0.49 0.56 e0.40
n Z (15 vs 46) (0.33-0.63) (0.43-0.68)
ity þ Specificity e 1); vs Z versus; nZ number of patients..
ning data were augmented before model training.
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Fig. 3. The receiver operating characteristics for Gleason score (left) and risk group (right) classification with ElasticNet.
Classifiers performance on training (top) and testing data (bottom) is presented.
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cated by the high values for their Spearman correlation
coefficients. A Venn diagram showing the intersections of
the top features selected by LASSO for different classifi-
cation problems is presented in Figure E3 (available online
at https://doi.org/10.1016/j.ijrobp.2019.06.2504).Discussion
In this study, the value of CT-based radiomics analysis in
prostate GS and risk group classification is demonstrated.
This work describes the extraction of quantitative imaging
features and the application of machine learning methods
for features selection and reduction and model training. A
testeretest analysis was conducted to investigate the
robustness and stability of extracted features and to elimi-
nate nonreliable features. Given the retrospective nature of
the database used in this study and limitations associated
with the variable scanerescan data (scanners, scan pa-
rameters, and time gap between scans), this testeretest
analysis is likely to eliminate more features than truly
required. However, this method was adopted to provide a
conservative measure to account for the variations in the
data set used in this analysis.Previous studies on prostate cancer radiomics mainly
focused on the use of mpMRI.8-11,30,32-38 Several studies
have demonstrated the value of mpMRI-based features for
prostate cancer detection,8,32-34 prostate cancer aggres-
siveness and GS classification,30,35 biochemical failure risk
prediction,36,37 and in targeted radiation therapy
planning.38
Fehr et al30 investigated the use of MRI-based texture
features in cancer detection and GS assessment in prostate
cancer patients. They showed that accurate models for GS
classification could be achieved by using machine-learning
methods to combine several apparent diffusion coefficients
ADC and T2 measures, even in highly imbalanced data
sets. Similar to our work, they also showed that using
sample augmentation methods always resulted in better
performing classification models in all the cases.
Only one study was found for perfusion-CTebased
radiomics for prostate cancer.7 Motivated by previous
studies showing the correlation of perfusion-CT parameters
with PSA values, GS, and TNM stage,39,40 Tanasini-Lang
et al7 investigated perfusion-CTebased radiomics for GS
classifications. In their study, before radical prostatectomy,
all patients (n Z 41) had perfusion CT, and perfusion pa-
rameters calculated from PO contours. Three perfusion
maps were calculated (ie, blood volume, blood flow (BF),
Volume 105  Number 2  2019 Prostate cancer CT-based radiomics 455mean transit time), and 1701 radiomics features from these
maps were calculated for each patient. Using principle
component analysis, 10 feature groups were identified.
From each group, a single radiomics feature (that correlated
best with the group) was chosen to represent the group in a
multivariate regression analysis to predict the postsurgical
GS. They found one radiomics feature, the HHL wavelet
transform of BF joint average, to be prognostic for GS (7 vs
>7). Comparing patients with GS 7(3 þ 4) versus GS 7(4
þ 3), both BF HHH fractal dimension and blood volume
HLH root mean square were found different between the
two groups. Interestingly, they also reported that for 28% of
patients there was a difference in grading between the bi-
opsy and postsurgical histopathology.7
Although it is not possible to correlate the CT-based
radiomics features in this study directly with previous work
on MRI or perfusion-CT, a general comparison of the
performance of final classification models is presented for
nonaugmented data. CT-based radiomics ElasticNet-based
classifiers of GS 6 versus GS > 6 (nZ 80 vs 194) achieved
an accuracy of 0.72 with YI Z 0.04 compared with 0.83
accuracy and YI Z 0.03 reported for the MRI-based clas-
sifier by Fehr et al30 (n Z 34 vs 159). Excellent perfor-
mance was observed in this work for classifiers of GS 7(3 þ
4) versus GS 7(4 þ 3) with Acc Z 0.98 and YI Z 0.80 (n
Z 70 vs 40) compared with Acc Z 0.83 and YI Z 0.11 in
Gamer et al24 (n Z 114 vs 26). CT-based classifier for GS
(7 vs >7) showed lower performance (AUC Z 0.69; Acc
Z 0.64) compared with perfusion-CT based models (AUC
Z 0.81)7; however, the number of patients in Tanadini-
Lang et al7 was much smaller (n Z 32 vs 8) than the
number of patients in the present study (n Z 109 vs 85).
In this study, the role of radiomics features in classifying
patients with prostate cancer into different risk groups was
also investigated. Despite the highly imbalanced data sets,
excellent apparent performance was observed for classifiers
of low versus high-risk group (nZ 26 vs. 187) groups (Acc
Z 0.98; AUC Z 1.00; YI Z 0.81) and low- versus
intermediate-risk groups ( Acc Z 1.00; AUC Z 1.00; YI
Z 1.00). However, poor performance was observed for
classifiers of intermediate versus high risk (Acc Z 0.75;
AUC Z 0.68; YI Z 0), Table E2 (available online at
https://doi.org/10.1016/j.ijrobp.2019.06.2504).
In all the studies discussed thus far, the data were used to
develop the models, and the performance of classifiers was
assessed using resampling techniques. In this study, clas-
sifiers were also tested on unseen data showing overall
modest performance. This result could be influenced by the
small number of patients in test data sets and by the class
imbalances. Nonetheless, this study shows that CT-based
radiomics features can provide insight into the nature of
prostate cancer beyond the scope of visual assessment. Our
models classified patients with low SG/RG versus high GS/
RG and with GS 7(3 þ 4) versus GS 7(4 þ 3) with high
accuracy. The developed classifiers were especially accu-
rate in identifying high-risk patients with a high Gleason
score. This study does not suggest replacing MRI-basedradiomics for prostate cancer risk assessment. This study
demonstrates that CT-based radiomics carry information
that can be used to improve current risk stratification
methods. Combining CT- and MRI-based radiomics could
give more accurate assessments of prostate cancer aggres-
siveness, and this subject needs further investigation. It is
acknowledged that this study has some limitations. First,
this is a retrospective study with no external validation data
set. In an ongoing study, three data sets for external vali-
dation are being prepared; the first data set is from our own
institution sampled from a later period (2010-2015), and
the two other cohorts will come from other external in-
stitutions. Moreover, radiomics features in this study were
extracted from the PO structures and not prostate cancer
explicitl. Although this is a more accurate representation of
current prostate cancer RT treatments, in several in-
vestigations on MRI-based prostate cancer, radiomics fea-
tures were found to be different in cancers arising in the
transitional zone from those in the peripheral zone of the
prostate.30,32 This limitation can be addressed in future
prospective studies by contouring suspicious areas of the
prostate on CT scans aided by MRI fusion.11 This tech-
nique is used in clinical practice for defining boost volumes
of dominant intraprostatic lesions. Cancer-specific con-
touring might also allow better understanding of the shape
features. Moreover, the endpoint in this study was GS based
on TRUS biopsies. It is expected that mpMRI guided bi-
opsies will provide more accurate grading of prostate
cancers and consequently allow the training of more ac-
curate image-based classifiers. Another observation in this
study was the correlation between prostate volume and
some of the radiomics features included in the final models.
As discussed by Welch at al41 on their work on radiomics
safeguards, this might have implications for models’ per-
formance and generalizability. Therefore, these correlations
between radiomics features and prostate volume should be
investigated thoroughly in future studies.
Despite these limitations, the current study is proof of
concept that standardly obtained pCT scans can reproduc-
ibly characterize risk stratification in prostate cancer and
can guide future studies investigating bespoke radiation
therapy based on CT radiomics. External validation and
prospective studies are warranted to verify our findings.References
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